The biomarker group within pRED Early Clinical Development Oncology is working on deciphering the complexity of human tumor- host biology by leveraging clinical trial biomarker data for oncology pipeline programs. The ultimate goal is to identify biomarkers that will tailor cancer therapies to patients.
We are seeking a highly motivated Biomarker & Experimental Medicine Leader (BEML) to join the group and help to lead the biomarker efforts for our pipeline molecules on cancer immunotherapy and molecular targeted therapies. In this role, you will be responsible for the analysis of high and low dimensional data for reverse translational applications, the development, execution and the oversight of biomarker strategies for two or more projects.
Responsibilities include, but are not limited to the following tasks:
Qualifications